ELAN Share Price | Elanco Animal Health, Inc. Stock Analysis & Recommendation

Q: What does Elanco Animal Health, Inc. do?

Overview:Elanco Animal Health, Inc. is an animal health company that develops, manufactures, and markets products for companion and food animals, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.Financial Snapshot:Net Sales: 1,193 Million (Quarterly Results - Mar 2025) Net Profit: 67 Million (Quarterly Results - Mar 2025) Market cap: USD 6,759.36 Million (Mid Cap)Key Metrics:P/E: 14.00 Dividend Yield: 0.00% Debt Equity: 0.62 Return on Equity: 8.05% Price to Book: 1.06 Contact Details:Address: 2500 Innovation Way N, GREENFIELD IN: 46140-9163 Website: https://www.elanco.com/

Q: Is Elanco Animal Health, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Elanco Animal Health, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands are bullish, while the monthly RSI is bearish, indicating mixed signals across different time frames. The daily moving averages are bullish, and the Dow Theory shows a mildly bullish stance on both weekly and monthly charts. In terms of performance, Elanco has outperformed the S&P 500 in the past week (1.70% vs. 1.05%) and month (7.91% vs. 2.33%), but it has underperformed over longer periods, particularly in the 3-year (29.49% vs. 70.41%) and 5-year (-28.03% vs. 96.61%) comparisons. Overall, the current stance is mildly bullish, with key indicators showing strength in the weekly MACD and Bollinger Bands.

Q: Is Elanco Animal Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Elanco Animal Health, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 14, an EV to EBITDA of 12.07, and a PEG ratio of 0.03, which suggests limited growth relative to its price. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of approximately 19.25 and 15.17, respectively, indicating that Elanco's valuation is less favorable in the context of its industry.Despite strong recent performance, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term outlook appears less optimistic, as evidenced by a 5-year return of -32.09% against the S&P's 91.29%. This disparity in long-term performance further supports the conclusion that Elanco Animal Health, Inc. is currently overvalued.

Results Declared: Elanco Animal Health, Inc. has declared results on 06 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.4 M

Shareholding (Mar 2026)

FII

14.97%

Held by 185 FIIs

DII

17.2%

Held by 128 DIIs

Promoter

0.72%

How big is Elanco Animal Health, Inc.?

22-Jun-2025

As of Jun 18, Elanco Animal Health, Inc. has a market capitalization of $6.76 billion, with net sales of $4.43 billion and a net profit of $373 million over the latest four quarters. Shareholder's funds are reported at $6.10 billion, and total assets amount to $12.61 billion.

View full answer

What does Elanco Animal Health, Inc. do?

22-Jun-2025

Elanco Animal Health, Inc. develops and markets products for companion and food animals, with net sales of $1.193 billion and a market cap of approximately $6.76 billion. Key metrics include a P/E ratio of 14.00 and a return on equity of 8.05%.

View full answer

Who are in the management team of Elanco Animal Health, Inc.?

22-Jun-2025

As of March 2022, the management team of Elanco Animal Health, Inc. includes R. David Hoover (Independent Chairman), Jeffrey Simmons (President & CEO), and several Independent Directors: William Doyle, Kapila Anand, John Bilbrey, Scott Ferguson, and Art Garcia. They oversee the company's strategic direction and operations.

View full answer

Is Elanco Animal Health, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Elanco Animal Health, Inc. shows a mildly bullish trend with strong weekly indicators, outperforming the S&P 500 recently, but underperforming over the longer term.

View full answer

Is Elanco Animal Health, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Elanco Animal Health, Inc. is considered overvalued with a valuation grade shift from very attractive to expensive, reflected by its lower P/E ratio compared to peers and poor long-term performance despite strong recent gains.

View full answer

Compare Elanco Animal Health, Inc. with Similar Stocks

Bio-Techne Corp.BioMarin Pharmaceutical, Inc.Illumina, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 11,634 Million (Small Cap)

P/E

104.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.52

Return on Equity

1.65%

Price to Book

1.72

Revenue and Profits:

Net Sales:

1,371 Million

(Quarterly Results - Mar 2026)

Net Profit:

57 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.15%

6 Months

10.05%

1 Year

92.59%

2 Years

40.02%

3 Years

152.67%

4 Years

-0.59%

5 Years

-28.07%

Elanco Animal Health, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.47%

EBIT Growth (5y)

18.65%

EBIT to Interest (avg)

0.90

Debt to EBITDA (avg)

5.95

Net Debt to Equity (avg)

0.62

Sales to Capital Employed (avg)

0.39

Tax Ratio

30.41%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

2.12%

ROE (avg)

2.44%

Valuation key factors

Factor

Value

P/E Ratio

104

Industry P/E

Price to Book Value

1.72

EV to EBIT

62.87

EV to EBITDA

16.63

EV to Capital Employed

1.48

EV to Sales

3.30

PEG Ratio

Dividend Yield

ROCE (Latest)

2.35%

ROE (Latest)

1.65%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 92 Schemes (67.06%)

Foreign Institutions

Held by 185 Foreign Institutions (14.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 19.84% vs 0.62% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 120.65% vs -711.76% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,371.00",
          "val2": "1,144.00",
          "chgp": "19.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "341.00",
          "val2": "193.00",
          "chgp": "76.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "73.00",
          "val2": "91.00",
          "chgp": "-19.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-17.00",
          "val2": "-194.00",
          "chgp": "91.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "57.00",
          "val2": "-276.00",
          "chgp": "120.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "123.30%",
          "val2": "16.60%",
          "chgp": "10.67%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.22% vs 0.50% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -168.64% vs 127.46% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,715.00",
          "val2": "4,439.00",
          "chgp": "6.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "932.00",
          "val2": "913.00",
          "chgp": "2.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "300.00",
          "val2": "339.00",
          "chgp": "-11.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-203.00",
          "val2": "-172.00",
          "chgp": "-18.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-232.00",
          "val2": "338.00",
          "chgp": "-168.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "53.40%",
          "val2": "56.50%",
          "chgp": "-0.31%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

1,371.00

1,144.00

19.84%

Operating Profit (PBDIT) excl Other Income

341.00

193.00

76.68%

Interest

73.00

91.00

-19.78%

Exceptional Items

-17.00

-194.00

91.24%

Consolidate Net Profit

57.00

-276.00

120.65%

Operating Profit Margin (Excl OI)

123.30%

16.60%

10.67%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 19.84% vs 0.62% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 120.65% vs -711.76% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

4,715.00

4,439.00

6.22%

Operating Profit (PBDIT) excl Other Income

932.00

913.00

2.08%

Interest

300.00

339.00

-11.50%

Exceptional Items

-203.00

-172.00

-18.02%

Consolidate Net Profit

-232.00

338.00

-168.64%

Operating Profit Margin (Excl OI)

53.40%

56.50%

-0.31%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 6.22% vs 0.50% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -168.64% vs 127.46% in Dec 2024

All Annual Results

Company CV

About Elanco Animal Health, Inc.

Elanco Animal Health, Inc.

Pharmaceuticals & Biotechnology

Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.

Company Coordinates

Company Details

2500 Innovation Way N , GREENFIELD IN : 46140-9163

Tel:

https://www.elanco.com/

Registrar Details